NCT01311661 - A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2011

Conditions

Asthma

Interventions

DRUG

Placebo twice daily

Inhaled Placebo of Olodaterol twice daily

DRUG

Olodaterol low daily dose twice daily

Inhaled Olodaterol medium daily dose administered as low dose twice daily

DRUG

Olodaterol medium daily dose twice daily

Inhaled Olodaterol high daily dose administered as medium dose twice daily

DRUG

Placebo twice daily

Inhaled Placebo of Olodaterol twice daily

DRUG

Olodaterol high daily dose once daily and placebo

Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily

DRUG

Olodaterol medium daily dose once daily and placebo

Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily

Trial Locations (36)

Unknown

1222.29.11006 Boehringer Ingelheim Investigational Site, Huntington Beach

1222.29.11001 Boehringer Ingelheim Investigational Site, Centennial

1222.29.11012 Boehringer Ingelheim Investigational Site, Wheat Ridge

1222.29.11002 Boehringer Ingelheim Investigational Site, Overland Park

1222.29.11004 Boehringer Ingelheim Investigational Site, North Dartmouth

1222.29.11011 Boehringer Ingelheim Investigational Site, St Louis

1222.29.11009 Boehringer Ingelheim Investigational Site, Skillman

1222.29.11003 Boehringer Ingelheim Investigational Site, Raleigh

1222.29.11008 Boehringer Ingelheim Investigational Site, Canton

1222.29.11007 Boehringer Ingelheim Investigational Site, Cincinnati

1222.29.11005 Boehringer Ingelheim Investigational Site, Spartanburg

1222.29.11010 Boehringer Ingelheim Investigational Site, Richmond

1222.29.43003 Boehringer Ingelheim Investigational Site, Linz

1222.29.43002 Boehringer Ingelheim Investigational Site, Schlüsslberg

1222.29.43001 Boehringer Ingelheim Investigational Site, Thalheim bei Wels

1222.29.43004 Boehringer Ingelheim Investigational Site, Wels

1222.29.49004 Boehringer Ingelheim Investigational Site, Berlin

1222.29.49006 Boehringer Ingelheim Investigational Site, Berlin

1222.29.49007 Boehringer Ingelheim Investigational Site, Berlin

1222.29.49008 Boehringer Ingelheim Investigational Site, Berlin

1222.29.49002 Boehringer Ingelheim Investigational Site, Frankfurt

1222.29.49010 Boehringer Ingelheim Investigational Site, Großhansdorf

1222.29.49003 Boehringer Ingelheim Investigational Site, Lübeck

1222.29.49005 Boehringer Ingelheim Investigational Site, Rüdersdorf

1222.29.49001 Boehringer Ingelheim Investigational Site, Wiesbaden

1222.29.49009 Boehringer Ingelheim Investigational Site, Wiesloch

1222.29.36002 Boehringer Ingelheim Investigational Site, Mosonmagyaróvár

1222.29.36003 Boehringer Ingelheim Investigational Site, Nyíregyháza

1222.29.36001 Boehringer Ingelheim Investigational Site, Sopron

1222.29.36004 Boehringer Ingelheim Investigational Site, Zalaegerszeg

1222.29.42001 Boehringer Ingelheim Investigational Site, Bardejov

1222.29.42002 Boehringer Ingelheim Investigational Site, Martin

1222.29.42004 Boehringer Ingelheim Investigational Site, Nitra

1222.29.42003 Boehringer Ingelheim Investigational Site, Spišská Nová Ves

1222.29.38003 Boehringer Ingelheim Investigational Site, Golnik

1222.29.38002 Boehringer Ingelheim Investigational Site, Kamnik